戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 oss through the induction of host damage and immunostimulation.
2 loss by inducing gingival damage followed by immunostimulation.
3 apies that suppress the immune system toward immunostimulation.
4 fied as necessary and sufficient to suppress immunostimulation.
5  of yeast tRNA(Phe) also resulted in blocked immunostimulation.
6 tional modifications as a factor suppressing immunostimulation.
7 roflora elicited age- and cell type-specific immunostimulation.
8 ry effect of these supernatants on normal DC immunostimulation.
9 tability, rapid body clearance, and unwanted immunostimulation.
10 us to prepare "designer" CRCL, utilizing the immunostimulation activity and the carrying capacity of
11 l responses that are strongly potentiated by immunostimulation (agonist anti-OX40).
12 unosuppressive tumor microenvironment toward immunostimulation and improves drug delivery and therape
13  novel therapeutic to simultaneously provide immunostimulation and lessen immunosuppression associate
14 mune cell factor release can be modulated by immunostimulation and steroid suppression.
15 ts suggest that IMOs induce strong and rapid immunostimulation and that the CpR dinucleotide is recog
16 -inflammatory cytokine responses to systemic immunostimulation and underscore the importance of perfo
17 pid clearance by reticuloendothelial organs, immunostimulation, and coagulopathies, limit their appli
18  been proposed for patient stratification in immunostimulation approaches.
19 nstead of inhibiting it (a phenomenon called immunostimulation), as opposed to active vaccination pro
20 igher level in animals resulted in prolonged immunostimulation, as confirmed preclinically by the rec
21 seful means of elucidating the mechanisms of immunostimulation by bacterial DNA and CpG ODN as well a
22               To elucidate the mechanisms of immunostimulation by bacterial DNA and synthetic oligonu
23 y of oncolytic virotherapy: incorporation of immunostimulation by cytokine and checkpoint inhibitor p
24 uency of CG dinucleotides in the genome, and immunostimulation by DNA occurred in the order E. coli >
25              The enhanced T cell and NK cell immunostimulation by GM-CSF DC was in part dependent on
26                                              Immunostimulation by i.d. LT(G33D) is explained by its a
27                                 The variable immunostimulation by microbes that has been charted in r
28 ess sufficient to cause marked inhibition of immunostimulation by normal uninfected moDCs.
29 ed relative to its murine "parent" to permit immunostimulation by repetitive i.v. administration.
30 induction complicates gene function studies, immunostimulation by siRNAs may be beneficial in certain
31 s blocked by bafilomycin A1, indicating that immunostimulation by U1 RNA requires endosomal acidifica
32  vaccine development, immunosuppression, and immunostimulation for various diseases.
33                                The degree of immunostimulation greatly depended on the size, shape an
34  low IL-6 levels), while other mice die with immunostimulation (high IL-6 levels and bacterial growth
35 ayed in whole-blood spots as an indicator of immunostimulation; (ii) skinfold thickness, to estimate
36 fication of patients that could benefit from immunostimulation in the context of personalized medicin
37  actions, including hematologic recovery and immunostimulation in the face of chemosuppression.
38                                        IL-12 immunostimulation induces a strong immunosuppressive rea
39 er CpG oligonucleotides (ODNs) for sustained immunostimulation is reported.
40 in in vivo activity via antigen delivery and immunostimulation mechanisms.
41 he course of our work that aims at promoting immunostimulation of APCs by inhibition of negative regu
42 s the need for more research focusing on the immunostimulation of different early developmental stage
43                                              Immunostimulation of J774.2 macrophages with endotoxin r
44                                Thus, in vivo immunostimulation of NK cells, a promising therapeutic a
45 e bioterrorism agents that cause diseases by immunostimulation or cytotoxicity.
46 anism for determining whether IL-10 leads to immunostimulation or immunosuppression in vivo.
47                           We show that local immunostimulation performed by injecting cytokines and T
48  cancer, and is a promising target for local immunostimulation, promoting intratumoral inflammation,
49                             Studies indicate immunostimulation represents a viable therapy for patien
50 tic agent via BNPs, with or without adjuvant immunostimulation, represents a viable, nonsurgical alte
51 oid cell-specific deletion in mice, in which immunostimulation resulted in hypersensitive neutrophils
52                                 Experimental immunostimulation using the PHA (phytohaemagglutinin ass
53                                        Thus, immunostimulation via alphaCD40 is sufficient to synergi
54                      This demonstration that immunostimulation via CD40 can replace CD4 T cell help i
55                                              Immunostimulation was documented at both local and syste
56 ese observations suggest that intrapulmonary immunostimulation with TNF can reverse sepsis-induced im
57  to explore the possible antiviral effect of immunostimulation with ZOL in this context.